No Data
No Data
Acma Swings to Loss in H2 2023 as Revenue Falls 14.5%
Acma (SGX:AYV) posted SG$2.8 million in attributable loss in the second half of 2023, versus an attributable profit of SG$159,000 in the year-ago period, according to a Friday filing. Diluted loss per
Acma to Sell Mold Manufacturing Unit in China
Acma's (SGX:AYV) wholly-owned indirect subsidiary, Global Tech, agreed to sell Acot Tooling (Xiamen), a manufacturer of molds in China, to Fong Choy Yoke for a nominal cash consideration of SG$1, acco
ACMA Introduces First Ever Accredited, Professional Certification for Specialty Pharmaceutical Sales Professionals
NEW YORK, Nov. 14, 2023 /PRNewswire/ -- The Accreditation Council for Medical Affairs (ACMA), a globally recognized leader and the first and only accrediting body for the pharmaceutical industry, tod
BenevolentAI: Appointment Of Catherine Isted, ACMA, As Chief Financial Officer >BAI.AE
BenevolentAI: Appointment Of Catherine Isted, ACMA, As Chief Financial Officer >BAI.AE
New Web Platform Launched by the ACMA to Empower Healthcare Providers in Reporting Unethical Practices by Pharma Reps and Medical Science Liaisons
NEW YORK, April 11, 2023 /PRNewswire/ -- The Accreditation Council for Medical Affairs (ACMA), a globally recognized leader and the first and only accrediting body for the pharmaceutical industry ann
THE ACCREDITATION COUNCIL FOR MEDICAL AFFAIRS (ACMA) DEVELOPS FIRST EVER BOARD-CERTIFIED BIOLOGICS & BIOSIMILARS SPECIALIST (BCBBS) CERTIFICATION
NEW YORK, Dec. 6, 2022 /PRNewswire/ -- The Accreditation Council for Medical Affairs (ACMA) is launching a new Board Certification program focused on biologics and biosimilars. This is the first and
No Data